Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Docetaxel trihydrate (RP-56976 Trihydrate) 是一种抗肿瘤试剂,抑制微管解聚的IC50值为 0.2 μM。它是紫杉醇的半合成类似物,能减弱 bcl-2 和 bcl-xL 基因表达的影响。它阻滞G2/M 细胞周期,导致细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 327 | 现货 | ||
100 mg | ¥ 460 | 现货 | ||
500 mg | ¥ 1,110 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 240 | 现货 |
产品描述 | Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis. |
体外活性 | 每4天注射3次33 mg/kg Docetaxel导致M2OL2结肠癌异种移植瘤的生长延迟19.3天.在MX-1,SK-MEL-2,LX-1和OVCAR-3 异种移植物中,Docetaxel具有良好的抗肿瘤活性.一周注射两次Docetaxel,持续14天,抑制成纤维细胞生长因子2的血管生成反应,IC 50为5.4 mg/kg.当给药10 mg/kg Docetaxel时,会完全抑制小鼠的血管生成. |
体内活性 | Docetaxel抑制人癌细胞Hs746T (胃),AGS (胃),HeLa (子宫颈),CaSki (子宫颈),BxPC3 (胰腺),Capan-1 (胰腺)的克隆存活,IC50 分别为1 nM,1 nM,0.3 nM,0.3 nM,0.3 nM 和 0.3 nM。DDocetaxel可以抑制两个血管生成因子,胸苷磷酸化酶或VEGF刺激的人脐静脉血管内皮细胞趋药性,IC50 为10 pM。Docetaxel诱导人单核细胞,而不影响RAW 264.7 小鼠巨噬细胞中前列腺素H 合酶-2m (PGHS-2)的表达。 |
细胞实验 | 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO2. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader. (Only for Reference) |
别名 | RP-56976 (Trihydrate), RP56976 (NSC 628503) Trihydrate, 多西他赛三水合物 |
分子量 | 861.95 |
分子式 | C43H59NO17 |
CAS No. | 148408-66-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 100 mg/mL (116.01 mM)
DMSO: 100 mg/mL (116.01 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.1602 mL | 5.8008 mL | 11.6016 mL | 29.004 mL |
5 mM | 0.232 mL | 1.1602 mL | 2.3203 mL | 5.8008 mL | |
10 mM | 0.116 mL | 0.5801 mL | 1.1602 mL | 2.9004 mL | |
20 mM | 0.058 mL | 0.29 mL | 0.5801 mL | 1.4502 mL | |
50 mM | 0.0232 mL | 0.116 mL | 0.232 mL | 0.5801 mL | |
100 mM | 0.0116 mL | 0.058 mL | 0.116 mL | 0.29 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Docetaxel trihydrate 148408-66-6 Apoptosis Cytoskeletal Signaling Microtubule Associated BCL inhibit RP-56976 (Trihydrate) Inhibitor RP-56976 RP56976 (NSC 628503) Trihydrate Docetaxel Trihydrate 多西他赛三水合物 Microtubule/Tubulin RP56976 Docetaxel RP56976 (NSC 628503) RP 56976 inhibitor